Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698826 · ClinicalTrials.gov registry record · Phase 1
Reoxygenation After Cardiac Arrest II (REOX II Study)
A Phase 1 study of Cardiac Arrest, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT02698826: Completed Phase 1 study of Cardiac Arrest, sponsored by The Cooper Health System.
NCT02698826 is a Phase 1 study of Cardiac Arrest that has completed, run by The Cooper Health System. The registered enrollment target is 16 participants, below the 1,479-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02698826, a Phase 1 study of Cardiac Arrest, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. After obtaining written informed consent subjects enrolled in REOX II will undergo a rapid faction of inspired oxygen (FiO2) optimization protocol to prevent exposure to hyperoxia. We will compare outcomes between subjects enrolled in REOX I (observational study only) and REOX II (intervention: rapid FiO2 optimization protocol). Our overarching hypothesis is that exposure to hyperoxia after return of spontaneous circulation (ROSC) is associated with increased oxidative stress and worsened neurological and cognitive outcomes.
Conditions Studied
Interventions
- OTHER Protocol for rapid FiO2 optimization
Study Locations (5)
Indiana
- Indiana University/ Methodist Hospital - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Mississippi
- University of Mississippi Medical Center - Jackson
New Jersey
- Cooper University Hospital - Camden
Pennsylvania
- Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-10 |
| Phase | Phase 1 |
What the finished NCT02698826 record still lists
NCT02698826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,479-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cardiac Arrest appearing as the primary indexed condition, and to 1 intervention - of which Protocol for rapid FiO2 optimization is the first listed.
NCT02698826 lists 5 locations in 5 states (Indiana, Massachusetts, Mississippi).
Frequently Asked Questions
What is clinical trial NCT02698826 about?
NCT02698826 is a clinical study titled "Reoxygenation After Cardiac Arrest II (REOX II Study)". The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. After obtaining written informed consent subjects enrolled in REOX II will undergo a rapid faction of inspired oxygen (FiO2) optimization protocol to prevent e...
What is the current status of trial NCT02698826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-04. Estimated completion is 2018-10.
What conditions does trial NCT02698826 study?
This clinical trial studies the following conditions: Cardiac Arrest.
What interventions are being tested in trial NCT02698826?
The interventions under investigation include: Protocol for rapid FiO2 optimization (OTHER).
Who is sponsoring clinical trial NCT02698826?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02698826 being conducted?
This trial has 5 study locations across Indiana, Massachusetts, Mississippi, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Arrest
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02698826's enrollment target sits among peer trials
16 27th of 31 higher than 4 of 31 other Cardiac Arrest trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Arrest trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-CA Neuroprotection With Magnesium
RECRUITING · Phase 1
-
Hydrogen's Feasibility and Safety as a Therapy in ECPR
RECRUITING · Phase 1
-
Packed Red Blood Cell Transfusion During Cardiac Arrest
RECRUITING · Phase 1
-
Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
COMPLETED · Phase 1
-
Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest
COMPLETED · Phase 1
-
Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia